November 11, 2016

Proton Pump Inhibitors and Risk of Incident CKD & Progression to ESRD

.   .   

The Department of Veterans Affairs national databases were used in this study to build a primary cohort of new users of PPI (n=173,321) and new users of histamine H2-receptor antagonists (H2blockers; n=20,270.  These patients were followed for over 5 years to ascertain renal outcomes. In adjusted Cox survival models, the PPI group, compared with the H2 blockers group, had an increased risk of incident eGFR<60 ml/min per 1.73 m2 and of incident CKD (HR, 1.22). Patients treated with PPI also had a significantly elevated risk of doubling of serum creatinine level (HR, 1.53), of eGFR decline >30% (HR, 1.32), and of ESRD (HR, 1.96).

Related Articles:

Chronic Kidney Disease, Clinical Nephrology, General Nephrology